Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Prostate Clear all

Conditions: Prostate Cancer
Interventions: CXCR2 as a biomarker; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: San Francisco, California • Ann Arbor, Michigan • Durham, North Carolina + 1 more

Conditions: Prostate Cancer
Interventions: custom device to demonstrate a significant difference in electrical impedance signatures; Device
Lead sponsor: Ryan J. Halter; Other
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions: Radiation therapy, Leuprolide, Relugolix; Radiation · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate, Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
Interventions: SYS6043; Drug
Lead sponsor: Conjupro Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Plantation, Florida • Austin, Texas • San Antonio, Texas + 1 more

Conditions: Prostate Cancer, Localized Prostate Carcinoma
Interventions: Microboost SBRT, Whole gland de-escalation 30 Gy, Whole gland de-escalation 35 Gy; Radiation
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Recurrent Prostate Cancer
Interventions: ADXS-504; Drug
Lead sponsor: Mark Stein; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary
Interventions: CC-486, Vidaza; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 10
States / cities: Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more

Conditions: Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction Following Simple Prostatectomy, Erectile Dysfunction
Interventions: Cognitive-behavioral Meetings, sildenafil citrate, Vacuum Constriction Device; Behavioral · Drug · Device
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 21 Years and older · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Neoplasms, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site, Prostatic Disease, Salivary Gland Cancer, Salivary Gland Tumor, Adenoid Cystic Carcinoma, Salivary Duct Carcinoma, Mucoepidermoid Carcinoma, Acinic Cell Tumor
Interventions: P-PSMA-101 CAR-T cells, Rimiducid; Biological · Drug
Lead sponsor: Poseida Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 10
States / cities: Duarte, California • San Diego, California • San Francisco, California + 6 more

Conditions: Prostate Cancer
Interventions: 125-Iodine, 103-palladium; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 13
States / cities: Phoenix, Arizona • Fresno, California • Aurora, Colorado + 10 more

Conditions: Prostate Cancer
Interventions: Gleevec, Docetaxel; Drug
Lead sponsor: Leonard Appleman; Other
Eligibility: 18 Years and older · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Cancer
Interventions: Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: Adam Olson; Other
Eligibility: 18 Years and older · Male only
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions: Patient Navigation, Genetic Counseling, Survey Administration, Best Practice; Behavioral · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: Estramustine, Thalidomide, Paclitaxel (Taxol); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adenocarcinoma of the Prostate, Hormone-refractory Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions: eribulin mesylate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 147
States / cities: Scottsdale, Arizona • Monterey, California • Manchester, Connecticut + 99 more

Conditions: Prostate Cancer
Interventions: high-intensity focused ultrasound ablation; Procedure
Lead sponsor: EDAP Technomed; Industry
Eligibility: 50 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 2
States / cities: San Francisco, California • Houston, Texas

Conditions: Prostate Cancer
Interventions: docetaxel, estramustine, mitoxantrone, prednisone; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 770 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 16
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 13 more

Conditions: Adenocarcinoma of the Prostate
Interventions: Lycopene and Docetaxel; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Prostate Cancer
Interventions: Abiraterone acetate, Dutasteride, Prednisone; Drug
Lead sponsor: Mary-Ellen Taplin, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 4
States / cities: Boston, Massachusetts • Seattle, Washington

Conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer
Interventions: 111Indium CHX-A; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: Prostate Biopsy, Focal Brachytherapy , Assessment of QOL; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 3
States / cities: New Hyde Park, New York • New York, New York • Houston, Texas

Conditions: Prostate Cancer, Biochemically Recurrent
Interventions: 18F-DCFpyL; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: educational CD-ROM; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 45 Years and older · Male only
Enrollment: 554 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Adenocarcinoma
Interventions: High Intensity Interval Training; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

COMPASS Study for Metastatic Castration-resistant Prostate Cancer

Microendoscopic EI Sensing for Real-time Intraoperative Surgical Margin Assessment

RElugolix VErsus LeUprolide Cardiac Trial

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer

Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Improving Erectile Function and Quality of Life After Prostate Cancer Treatment

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy

A Study of Imatinib and Docetaxel in Prostate Cancer

Hypofractionated SBRT For Prostate Cancer

Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation

Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma

Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Ultrasound in Treating Patients With Recurrent Stage I or Stage II Prostate Cancer

S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy

Docetaxel and Lycopene in Metastatic Prostate Cancer

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer

Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer

Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL

CD-ROM Intervention for Prostate Cancer Screening

Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients